Fig. 2: Antitumor activity of UCART123 against primary BPDCN samples in vitro. | Nature Communications

Fig. 2: Antitumor activity of UCART123 against primary BPDCN samples in vitro.

From: Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells

Fig. 2: Antitumor activity of UCART123 against primary BPDCN samples in vitro.The alternative text for this image may have been generated using AI.

a Expression of CD123 in CAL-1 cells and BPDCN patient samples was evaluated for 7 out of 8 samples by flow cytometry using 7G3 monoclonal anti-CD123-FITC antibody after gating on viable cells (DAPI−). b Specific cytotoxic activity against target cells (CD123+ MOLM13 cells and primary BPDCN samples) upon co-culture for 16 h with either UCART123 cells or TCRαβ KO T cells at E:T = 10:1. Each point represents the data obtained from triplicate experiments, and the mean ± SD value is presented. c CD107α degranulation was measured by flow cytometry after gating on CD8+ cells. “T cells” correspond to the basal activity of unstimulated T cells, and PMA/Ion corresponds to the signal observed upon nonspecific PMA/ionomycin stimulation. Degranulation activity upon co-culture of UCART123 or TCRαβ KO T cells with CD123- Jurkat cells as well as CD123+ MOLM13 cells and five different primary BPDCN samples is shown. Each point represents the data obtained from triplicate experiments, and the mean ± SD value is presented. d IFNγ release upon co-culture of UCART123 cells or TCRαβ KO T cells with CD123− or CD123+ cells at E:T = 1:1 for 25 h. IFNγ levels were determined using the BioLegend LEGENDplex assay. PMA/ionomycin was used as a positive control. Each point represents the data obtained from triplicate experiments, and the mean ± SD value is presented. BPDCN-1, 2, 4 were not tested in all assays due to limited cell numbers. Source data are provided as a Source data file.

Back to article page